MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Precipio Retained Earnings 2011-2026 | PRPO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Precipio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -103 M | -102 M | -98.2 M | -92.3 M | -80.1 M | -71.6 M | -60.9 M | -47.7 M | -31.5 M | -225 M | -213 M | -184 M | -169 M | -152 M | -143 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -31.5 M | -225 M | -118 M |
Quarterly Retained Earnings Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -103 M | -103 M | -103 M | -102 M | -102 M | -101 M | -100 M | -98.2 M | -99.1 M | -97.6 M | -95.3 M | -92.3 M | -90 M | -86.8 M | -84.7 M | -80.1 M | -77.9 M | -76 M | -73 M | -71.6 M | -71.6 M | -71.6 M | -71.6 M | -60.9 M | -60.9 M | -60.9 M | -60.9 M | -47.7 M | -47.7 M | -47.7 M | -47.7 M | -31.5 M | -31.5 M | -31.5 M | -31.5 M | -10.8 M | -10.8 M | -10.8 M | -225 M | -213 M | -213 M | -213 M | -213 M | -184 M | -184 M | -184 M | -184 M | -169 M | -169 M | -169 M | -169 M | -152 M | -152 M | -152 M | -152 M | -143 M | -143 M | -143 M | -143 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -10.8 M | -225 M | -107 M |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 114.78 | -0.61 % | $ 34.9 B |  USA |
|
Biodesix
BDSX
|
-462 M | $ 15.7 | 4.18 % | $ 2.04 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.15 | -0.83 % | $ 4.94 M | USA |
 |
BioNano Genomics
BNGO
|
-720 M | $ 1.16 | -3.33 % | $ 6.32 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 16.33 | 0.8 % | $ 176 M |  China |
 |
CareDx, Inc
CDNA
|
-735 M | $ 18.12 | -1.04 % | $ 966 M | USA |
 |
Celcuity
CELC
|
-449 M | $ 114.33 | 1.5 % | $ 5.35 B | USA |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 166.88 | -4.03 % | $ 8.27 B | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 25.0 | 0.64 % | $ 694 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Danaher Corporation
DHR
|
46.9 B | $ 191.23 | 0.06 % | $ 136 B | USA |
 |
DexCom
DXCM
|
2.43 B | $ 63.01 | 1.26 % | $ 24.6 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
590 M | $ 16.56 | -1.55 % | $ 501 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 90.84 | -3.19 % | $ 11.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 111.1 | -2.71 % | $ 9.16 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 1.92 | -1.92 % | $ 8.49 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 126.95 | -0.34 % | $ 20.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | China |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 169.58 | -2.12 % | $ 29.2 B | USA |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 274.35 | 0.23 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 75.67 | -0.57 % | $ 5.11 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 494.14 | -0.84 % | $ 14.3 B | USA |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 256.28 | -0.29 % | $ 25.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.76 | 0.11 % | $ 441 M | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
ENDRA Life Sciences
NDRA
|
-110 M | $ 4.57 | -2.46 % | $ 3.6 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 7.98 | -0.25 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.51 | 1.01 % | $ 2.06 B | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.43 | 1.6 % | $ 390 M | USA |
 |
Natera
NTRA
|
-1.94 B | $ 204.77 | -1.54 % | $ 20.2 B | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.41 | 5.05 % | $ 423 M | USA |
 |
Personalis
PSNL
|
-550 M | $ 6.64 | 0.84 % | $ 393 M | USA |
 |
RadNet
RDNT
|
-95.4 M | $ 55.13 | 0.62 % | $ 4.15 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |